Univest
Univest
  • Markets

Symbiotec Pharmalab Initial Public Offering Opens August 24-27: Rs 1,757 Crore Issue Raises Rs 526 Crore from 34 Anchor Investors at Rs 938-988

  • August 24, 2026
  • Posted by: Neeraj Pandey
  • Category: IPO
No Comments
Symbiotec Pharmalab Initial Public Offering Opens August 24-27: Rs 1,757 Crore Issue Raises Rs 526 Crore from 34 Anchor Investors at Rs 938-988

Symbiotec Pharmalab IPO: Opens 24 Aug, closes 27 Aug. Issue: Rs 1,757 cr. Anchor allotment: Rs 526 cr from 34 investors. Price band: Rs 938-988 per share.

Quick Answer

Symbiotec Pharmalab’s Rs 1,757 crore initial public offering opened for public subscription on August 24, 2026, and closes August 27, 2026. The pharmaceutical and biotechnology company raised Rs 526 crore from 34 anchor investors ahead of the public opening. The price band is Rs 938-988 per share. The strong anchor book, comprising 34 institutional investors, reflects broad institutional confidence in the company’s business and valuation.

Table of Contents

Toggle
  • Symbiotec Pharmalab Initial Public Offering: Key Issue Details
  • What the Rs 526 Crore Anchor Book Means
  • How to Evaluate the Symbiotec Pharmalab Initial Public Offering
  • Frequently Asked Questions
    • When does Symbiotec Pharmalab initial public offering open and close?
    • How much did Symbiotec Pharmalab raise from anchor investors?
    • What is the price band for Symbiotec Pharmalab initial public offering?
    • What is Symbiotec Pharmalab’s business?
    • What is the GMP for Symbiotec Pharmalab initial public offering?
    • How do I apply for Symbiotec Pharmalab initial public offering?
    • What is the significance of 34 anchor investors?

Symbiotec Pharmalab Initial Public Offering: Key Issue Details

Parameter Detail
Issue Name Symbiotec Pharmalab Initial Public Offering
Issue Size Rs 1,757 crore
Open Date August 24, 2026
Close Date August 27, 2026
Price Band Rs 938 to Rs 988 per share
Anchor Allocation Rs 526 crore
Number of Anchor Investors 34
Sector Pharmaceuticals and Biotechnology

Click Here – Get Free Investment Predictions

What the Rs 526 Crore Anchor Book Means

Raising Rs 526 crore from 34 anchor investors signals institutional validation of the price band. Anchor investors are qualified institutional buyers who undergo detailed due diligence before committing capital. That 34 institutions collectively allocated Rs 526 crore suggests they assessed the company’s valuation as fair or attractive at Rs 938-988.

However, anchor investor participation does not guarantee a successful listing. Even IPOs with strong anchor books can list at discounts if market conditions turn negative or if the issue is priced aggressively. Evaluate the Symbiotec Pharmalab initial public offering on its own fundamental merits. Grey Market Premium figures for this initial public offering are available on unofficial platforms but should not be the basis for subscription decisions.

Screen Pharma Sector Stocks on Univest Screener

How to Evaluate the Symbiotec Pharmalab Initial Public Offering

Review from the RHP: revenue and profitability growth over the last three fiscal years, margins in pharmaceutical manufacturing, regulatory track record with USFDA and other global regulators, promoter background, use of proceeds, and valuation relative to listed pharma peers on PE and EV/EBITDA metrics. The RHP is available on the SEBI EDGAR portal.

Download the Univest iOS App or Univest Android App to track Symbiotec Pharmalab allotment and listing price.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

When does Symbiotec Pharmalab initial public offering open and close?

Ans. Symbiotec Pharmalab initial public offering opens August 24 and closes August 27, 2026. Price band Rs 938-988 per share. Issue size Rs 1,757 crore. Rs 526 crore raised from 34 anchor investors.

How much did Symbiotec Pharmalab raise from anchor investors?

Ans. Symbiotec Pharmalab raised over Rs 526 crore from 34 anchor investors ahead of the public subscription opening.

What is the price band for Symbiotec Pharmalab initial public offering?

Ans. The price band is Rs 938 to Rs 988 per share. Apply at the cut-off price to maximise allotment probability.

What is Symbiotec Pharmalab’s business?

Ans. Symbiotec Pharmalab is a pharmaceutical and biotechnology company. Full details are in the Red Herring Prospectus on SEBI EDGAR.

What is the GMP for Symbiotec Pharmalab initial public offering?

Ans. GMP may appear on unofficial sites like IPOWatch or Investorgain but is not reliable. Base decisions on company fundamentals from the RHP.

How do I apply for Symbiotec Pharmalab initial public offering?

Ans. Apply through your Demat account using ASBA or UPI on a SEBI-registered broker platform. The issue is open August 24-27, 2026. Verify all details from official BSE, NSE, or SEBI EDGAR.

What is the significance of 34 anchor investors?

Ans. 34 anchor investors committing Rs 526 crore signals broad institutional interest and validation of the Rs 938-988 price band. Anchor investors are QIBs who conduct detailed due diligence before participating.



IPO
Author: Neeraj Pandey
Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply